Table 2 Virological failure (confirmed HIV-1 RNA ≥ 1000 Copies/mL at or after week 24) by selected characteristics of participants and randomized adherence support intervention
Variable | Categories | N (%) | N (%) with virologic failure | Hazard ratio (95% CI), unadjusted | Hazard ratio (95% CI) adjusted for other variables shown |
|---|---|---|---|---|---|
Sex | Female | 155 | 87 (56%) | 1.52 (1.07, 2.15) | 1.30 (0.90, 1.86) |
Male | 123 | 52 (42%) | Reference | ||
Age at study entry (years) | < 30 | 46 | 35 (76%) | 2.14 (1.45, 3.17) | 1.96 (1.31, 2.94) |
≥ 30 | 232 | 104 (45%) | Reference | ||
HIV-1 RNA at study entry (copies/mL) | ≥ 10,000 | 170 | 104 (61%) | 2.61 (1.78, 3.84) | 2.20 (1.46, 3.32) |
< 10,000 | 108 | 35 (32%) | Reference | ||
CD4 count at study entry (cells/mm3) | < 200 | 154 | 94 (61%) | 2.15 (1.51, 3.08) | 1.73 (1.18 2.53) |
≥ 200 | 124 | 45 (36%) | Reference | ||
Resistance to any NRTI at screening | Yes | 104 | 58 (56%) | 1.49 (1.06, 2.10) | 1.74 (1.22, 2.48) |
No | 174 | 81 (47%) | Reference | ||
Duration of ART prior to study entry (years) | < 10 | 210 | 116 (55%) | 1.90 (1.21, 2.98) | 1.62 (1.03, 2.56) |
≥ 10 | 68 | 23 (34%) | Reference | ||
Randomized Adherence Support Intervention | CPI + SOC | 128 | 58 (45%) | 0.78 (0.55, 1.11) | 0.80 (0.56, 1.14) |
SOC | 132 | 71 (54%) | Reference | ||
Site didn’t participate in randomization | 18 | 10 (56%) | 0.88 (0.45, 1.72) | 0.82 (0.42, 1.63) | |